Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA.
J Neurol. 2011 Aug;258(8):1469-76. doi: 10.1007/s00415-011-5961-9. Epub 2011 Mar 2.
In many patients, optimal results after pallidal deep brain stimulation (DBS) for primary dystonia may appear over several months, possibly beyond 1 year after implant. In order to elucidate the factors predicting such protracted clinical effect, we retrospectively reviewed the clinical records of 44 patients with primary dystonia and bilateral pallidal DBS implants. Patients with fixed skeletal deformities, as well as those with a history of prior ablative procedures, were excluded. The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) scores at baseline, 1 and 3 years after DBS were used to evaluate clinical outcome. All subjects showed a significant improvement after DBS implants (mean BFMDRS improvement of 74.9% at 1 year and 82.6% at 3 years). Disease duration (DD, median 15 years, range 2-42) and age at surgery (AS, median 31 years, range 10-59) showed a significant negative correlation with DBS outcome at 1 and 3 years. A partition analysis, using DD and AS, clustered subjects into three groups: (1) younger subjects with shorter DD (n = 19, AS < 27, DD ≤ 17); (2) older subjects with shorter DD (n = 8, DD ≤ 17, AS ≥ 27); (3) older subjects with longer DD (n = 17, DD > 17, AS ≥ 27). Younger patients with short DD benefitted more and faster than older patients, who however continued to improve 10% on average 1 year after DBS implants. Our data suggest that subjects with short DD may expect to achieve a better general outcome than those with longer DD and that AS may influence the time necessary to achieve maximal clinical response.
在许多患者中,苍白球深部脑刺激(DBS)治疗原发性肌张力障碍的最佳效果可能在数月后显现,甚至在植入后 1 年以上。为了阐明预测这种持久临床效果的因素,我们回顾性地分析了 44 例原发性肌张力障碍患者和双侧苍白球 DBS 植入患者的临床记录。排除了有固定骨骼畸形和先前消融治疗史的患者。使用基线、DBS 后 1 年和 3 年的 Burke-Fahn-Marsden 肌张力障碍评定量表(BFMDRS)评分评估临床结果。所有患者在 DBS 植入后均表现出显著改善(1 年时平均 BFMDRS 改善 74.9%,3 年时改善 82.6%)。疾病持续时间(DD,中位数 15 年,范围 2-42)和手术年龄(AS,中位数 31 岁,范围 10-59)与 1 年和 3 年时的 DBS 结果呈显著负相关。采用 DD 和 AS 的分区分析将患者分为三组:(1)DD 较短的年轻患者(n = 19,AS < 27,DD ≤ 17);(2)DD 较短的老年患者(n = 8,DD ≤ 17,AS ≥ 27);(3)DD 较长的老年患者(n = 17,DD > 17,AS ≥ 27)。DD 较短的年轻患者受益更多、更快,而年龄较大的患者则在 DBS 植入后 1 年平均再改善 10%。我们的数据表明,DD 较短的患者可能比 DD 较长的患者获得更好的总体结果,而 AS 可能会影响达到最大临床反应所需的时间。